**Funding sources** All authors were employed by the University of Manchester at the time the study was conducted. MRC Health eResearch Centre Grant MR/K006665/1 supported the time and facilities of one investigator (E.K.).

**Conflicts of interest** C.E.M.G. reports receiving grants and speaker fees from Abbvie and Celgene; serving on advisory boards for Novartis, Sandoz, UCB Pharma and Lilly; grant funding, speaker fees and serving on advisory boards for Janssen and Pfizer; and grant funding from GSK‐Stiefel and Leo Pharma. D.M.A. reports grant funding from Abbvie and serving on advisory boards for Pfizer and GSK. The remaining authors state no conflict of interest.

[Plain language summary](http://dx.doi.org/10.1111/bjd.15351) available online

Psoriasis is a chronic inflammatory skin disease associated with high levels of psychosocial disability and impaired quality of life for prolonged periods.[1](#bjd15021-bib-0001){ref-type="ref"}, [2](#bjd15021-bib-0002){ref-type="ref"}, [3](#bjd15021-bib-0003){ref-type="ref"} Our previous systematic review on the global epidemiology of psoriasis identified 53 published epidemiological studies reporting on the prevalence and/or incidence of psoriasis in the general population.[4](#bjd15021-bib-0004){ref-type="ref"} In that review, we found estimates of the occurrence of psoriasis to vary markedly according to sex and geographic region. For example, reported adult psoriasis prevalence ranged from 1·3% in the U.K. \[95% confidence interval (CI) 1·21--1·39\][5](#bjd15021-bib-0005){ref-type="ref"} to 8·5% in Norway (95% CI 8·03--8·97).[6](#bjd15021-bib-0006){ref-type="ref"} However, previous studies on the epidemiology of psoriasis have lacked consistency in case definition, thereby limiting the value of between‐country comparisons, and provide very limited data on temporal trends in the incidence and prevalence of this important skin disorder. Nonetheless, accurate and timely information on the epidemiology of psoriasis is needed in order to understand the impact of this disease and to ensure that adequate resources are provided nationally and regionally for people affected by psoriasis.[7](#bjd15021-bib-0007){ref-type="ref"}, [8](#bjd15021-bib-0008){ref-type="ref"}

We also identified important knowledge gaps in understanding the natural history and burden of psoriasis.[4](#bjd15021-bib-0004){ref-type="ref"} Specifically, very few studies have focused on the incidence of psoriasis and even fewer on trends in the incidence over time. To date, no studies have simultaneously compared longitudinal trends in incidence, prevalence and mortality in patients with psoriasis. This is critical in order to determine whether the prevalence of psoriasis is increasing over time, and if so, whether this is driven by increasing trends in incidence (more new cases of psoriasis) or whether patients are nowadays living much longer with psoriasis due to reductions in early mortality.

Several studies have reported on excess mortality in patients with psoriasis. For example, both cardiovascular mortality[9](#bjd15021-bib-0009){ref-type="ref"} and all‐cause mortality[10](#bjd15021-bib-0010){ref-type="ref"} have been reported to be elevated in patients with psoriasis. Over the last 30 years, though, overall survival in the general population in the U.K. has increased reflecting better overall population health.[11](#bjd15021-bib-0011){ref-type="ref"} Given this, it is important to determine whether there have also been temporal changes in mortality in patients with psoriasis too, as this will impact on disease prevalence. As yet, it is unknown whether the mortality gap (the number of excess premature deaths) among patients with psoriasis is narrowing, widening or remaining unchanged over time.

Over 98% of the U.K. population are registered with a primary care general practitioner (GP)[12](#bjd15021-bib-0012){ref-type="ref"} and under the National Health Service (NHS), visits to the GP are free of charge. U.K. primary care has been largely computerized since around 1998, when incentives for leaving paper‐based systems were provided.[13](#bjd15021-bib-0013){ref-type="ref"} A number of large‐scale primary care databases have subsequently been developed, allowing researchers to answer important epidemiological questions using this routinely collected anonymized electronic health data. This study sets out to investigate the epidemiology of psoriasis in the U.K. using the Clinical Practice Research Datalink (CPRD), one of the largest U.K. primary care databases.[14](#bjd15021-bib-0014){ref-type="ref"}

Our aim was to determine trends in the incidence, prevalence and mortality of patients with psoriasis over 15 years in a large population‐based cohort study and examine how these epidemiological factors may have changed over time. In addition, we examined (i) whether there exists an association between latitude and incidence/prevalence; and (ii) whether or not the excess mortality in patients with psoriasis has changed over time.

Methods {#bjd15021-sec-0007}
=======

Data source {#bjd15021-sec-0008}
-----------

We used the CPRD, a large primary care database that holds complete electronic patient records (including diagnoses, prescriptions, test results and hospital referrals) from participating family practices across the U.K. A hierarchical clinical coding system (Read) is used to record diagnosis data. In the database build we used (to July 2014), data were available for 685 practices and 15 436 637 patients.

Psoriasis cohort {#bjd15021-sec-0009}
----------------

We extracted data from 1 January 1999 to 31 December 2013 and aggregated these into 15 separate years. Within each year, practice inclusion was determined by an internal CPRD data quality assessment algorithm. Practices that were rated as 'up to standard for research purposes' for the whole of a year were included for that year. Within each up‐to‐standard practice and year, all eligible patients had to be registered with the practice at the start of the year for follow‐up. Data on age, sex, neighbourhood deprivation, geographical region and removal from the database due to death or leaving the practice were available and complete for all patients. Neighbourhood deprivation was measured using the 2010 Index of Multiple Deprivation (IMD) for the practice postcode, categorized into quintiles; IMD is a composite score based on 38 indicators organized across seven different domains of deprivation (income, employment, health and disability, education, housing and services, living environment, and crime).[15](#bjd15021-bib-0015){ref-type="ref"}

Prevalent cases were those with at least one diagnostic psoriasis Read code in the database prior to the end of the year in question. Denominators for each year were all patients meeting the study eligibility criteria. Incident cases were patients with a first diagnosis Read code for psoriasis in the year in question. In calculating incidence rates, denominator counts were determined to be patients that were psoriasis‐free at the start of the year. Patients with prior codes for psoriasis or with codes for a history of psoriasis were excluded from both the numerator and denominator in determining incidence rates. For both incidence and prevalence, follow‐up time was calculated for each denominator case, so denominators could include patients who had died or transferred out of the practice mid‐year.

To investigate associations between psoriasis and mortality, for each person in our psoriasis incidence cohort we selected up to five control patients with no history of a diagnostic code for psoriasis, matched with regard to chronological age (5‐year bands), sex and practice. Each psoriasis case was assigned an index date based on the date of first diagnosis of psoriasis. All matched controls had to have had a consultation in the practice within ± 90 days of the case index date, with this set as the index date for the control, in order to ensure that patients with or without psoriasis were followed up by the same practice over similar time periods.

Statistical analysis {#bjd15021-sec-0010}
--------------------

All analyses were carried out using R version 3·1·2.[16](#bjd15021-bib-0016){ref-type="ref"} Incidence and prevalence rates (95% CIs) were calculated with indirect adjustment for age and sex using the epiR package.[17](#bjd15021-bib-0017){ref-type="ref"} All clinical code lists used in the study are available from [www.clinicalcodes.org](http://www.clinicalcodes.org).[18](#bjd15021-bib-0018){ref-type="ref"}

We used Cox proportional hazards regressions to investigate mortality in the matched cohort study. The models included index year (as a continuous variable), sex, age at index date in 20‐year bands and practice level IMD quintiles. The analysis was clustered by practice. Cohort entry and exit times were collapsed into monthly time windows. A fully factorial model was initially fitted and the higher‐order interactions were removed in a stepwise fashion according to Akaike Information Criterion and individual coefficient *P*‐values. The proportional hazards assumption was assessed by scatterplots of the model coefficients over time and statistical testing based on weighted residuals.

As a sensitivity analysis, we repeated the analyses in a cohort restricted to include only practices that contributed data continuously for the whole of the period from 1 January 1999 to 31 December 2013.

Finally, we examined the relationship between latitude (measured at the central points of the 13 geographic regions in the CPRD consisting of the 10 regions in England plus Scotland, Wales and Northern Ireland) and incidence/prevalence rates, using mixed‐effects linear regressions, controlling for year and practice‐level deprivation. Practice was set to be a random effect in the analysis.

Results {#bjd15021-sec-0011}
=======

Incidence and prevalence {#bjd15021-sec-0012}
------------------------

Yearly rates for incidence and prevalence of psoriasis, adjusted for age and sex differences between years are summarized in Table [1](#bjd15021-tbl-0001){ref-type="table-wrap"}. Overall, adjusted psoriasis incidence declined from 159 cases per 100 000 person years (95% CI 155--164) in 1999 to 129 per 100 000 person years (95% CI 126--133) in 2013, although most of this decline occurred after 2008 (Fig. [1](#bjd15021-fig-0001){ref-type="fig"}). Conversely, psoriasis prevalence rates increased from 2·3% (2297 cases per 100 000 person years) in 1999 to 2·8% (2815 per 100 000 person years) in 2013. Prevalence and incidence of psoriasis over time for both males and females, adjusted for year and sex, are shown in Figure [1](#bjd15021-fig-0001){ref-type="fig"}. The patterns were similar in both males and females. Unadjusted incidence and prevalence rates based on raw counts are presented in Table S1 (see Supporting Information).

###### 

Psoriasis prevalence and incidence per 100 000 person years; adjusted for age (95% confidence intervals)

  Year   Total       Male                Female                                                                                            
  ------ ----------- ------------------- ---------------- ----------- ------------------- ---------------- ----------- ------------------- ----------------
  1999   2 842 495   2297 (2279--2315)   159 (155--164)   1 387 393   2284 (2258--2311)   158 (151--165)   1 455 102   2315 (2290--2341)   161 (155--168)
  2000   3 510 428   2265 (2249--2282)   163 (158--167)   1 715 862   2251 (2228--2275)   163 (157--170)   1 794 566   2285 (2262--2308)   162 (156--169)
  2001   4 053 693   2261 (2246--2276)   164 (160--168)   1 981 188   2258 (2236--2280)   166 (160--172)   2 072 505   2270 (2249--2292)   163 (157--168)
  2002   4 524 286   2302 (2287--2316)   170 (166--174)   2 212 181   2293 (2272--2314)   166 (161--172)   2 312 105   2316 (2296--2336)   174 (169--180)
  2003   4 910 335   2350 (2336--2364)   172 (168--176)   2 400 429   2336 (2316--2356)   166 (161--172)   2 509 906   2370 (2350--2390)   178 (173--183)
  2004   5 219 699   2427 (2413--2441)   166 (163--170)   2 553 093   2419 (2399--2439)   163 (158--168)   2 666 606   2439 (2420--2459)   170 (165--175)
  2005   5 467 744   2496 (2482--2509)   165 (162--169)   2 673 380   2484 (2464--2504)   158 (153--163)   2 794 364   2511 (2492--2530)   173 (168--178)
  2006   5 590 290   2546 (2532--2559)   161 (158--165)   2 731 258   2530 (2510--2550)   154 (149--159)   2 859 032   2565 (2546--2584)   169 (164--174)
  2007   5 657 122   2598 (2585--2612)   165 (162--168)   2 763 463   2580 (2560--2600)   160 (155--165)   2 893 659   2622 (2602--2641)   170 (165--175)
  2008   5 784 107   2648 (2635--2662)   163 (160--167)   2 823 447   2634 (2614--2653)   162 (157--167)   2 960 660   2668 (2648--2687)   165 (160--170)
  2009   5 808 529   2695 (2682--2709)   155 (152--158)   2 832 154   2682 (2662--2702)   152 (147--156)   2 976 375   2713 (2694--2732)   159 (154--163)
  2010   5 724 132   2744 (2730--2758)   143 (140--146)   2 786 062   2734 (2714--2754)   140 (136--145)   2 938 070   2760 (2740--2779)   145 (141--150)
  2011   5 694 515   2767 (2753--2781)   140 (137--143)   2 766 330   2755 (2735--2776)   135 (131--140)   2 928 185   2785 (2766--2805)   144 (140--149)
  2012   5 648 960   2781 (2767--2795)   131 (128--134)   2 738 101   2765 (2745--2785)   126 (122--130)   2 910 859   2803 (2783--2823)   136 (132--141)
  2013   5 226 764   2815 (2800--2830)   129 (126--133)   2 525 879   2806 (2785--2827)   127 (123--132)   2 700 885   2830 (2810--2851)   131 (127--136)
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![(a) Incidence and (b) prevalence (95% confidence intervals) of psoriasis from 1999 to 2013 for both males and females.](BJD-176-650-g001){#bjd15021-fig-0001}

Psoriasis incidence plotted against age showed a strongly bimodal pattern (Fig. [2](#bjd15021-fig-0002){ref-type="fig"}). 'Late‐onset' psoriasis (categorized as being diagnosed \> 40 years of age) shows little difference in distribution between males and females. However, 'early‐onset' psoriasis showed clear differences with females being more likely to be diagnosed with psoriasis at an earlier age.

![Incidence of psoriasis by age at diagnosis for males and females, with Loess smoothers (males, solid line; females, dashed line). The graph has been split into panels for early‐ and late‐onset psoriasis.](BJD-176-650-g002){#bjd15021-fig-0002}

Both incidence and prevalence of psoriasis showed a positive relationship with latitude (Fig. [3](#bjd15021-fig-0003){ref-type="fig"}). Controlling for year, deprivation and practice, incidence increased by 6·5 cases per 100 000 for every degree increase in latitude (95% CI 4--9·1 cases per 100 000) and prevalence increased by 201 cases per 100 000 for every degree in latitude (95% CI 163·5--238·6 cases per 100 000). In South West England, mean psoriasis incidence was 144 (95% CI 138--150 cases per 100 000) and mean prevalence was 2323 (95% CI 2266--2380 cases per 100 000). In Scotland, mean psoriasis incidence was 174 (95% CI 167--181 cases per 100 000) and mean prevalence was 3060 (95% CI 2991--3128 cases per 100 000).

![Relationship between latitude and (a) incidence and (b) prevalence of psoriasis.](BJD-176-650-g003){#bjd15021-fig-0003}

Similar rates and trends in incidence and prevalence were observed when restricting the cohort to include patients only from practices contributing data for the whole period between 1999 and 2013 as a planned sensitivity analysis (Fig. S1, see Supporting Information).

Mortality {#bjd15021-sec-0013}
---------

The characteristics of the matched psoriasis cases and controls are summarized in Table [2](#bjd15021-tbl-0002){ref-type="table-wrap"}. Median follow‐up time was similar for psoriasis cases and controls (mean follow‐up time = 64 months).

###### 

Summary of characteristics of patients included in the mortality analysis (matched on practice, age, sex)

                                                   Psoriasis cases   Controls
  ------------------------------------------------ ----------------- -----------------
  *n*                                              104 441           508 457
  Male patients (% of *n*)                         49 787 (47·7%)    241 918 (47·6%)
  Deaths (% of *n*)                                6555 (6·3%)       29 395 (5·8%)
  Follow‐up (person years)                         6 693 444         32 732 726
  Mean months follow‐up (SD)                       64·1 (45)         64·4 (45·2)
  Age (% of *n*), years                                              
  0--19                                            12 633 (12·1%)    66 048 (13%)
  20--39                                           30 946 (29·6%)    147 051 (28·9%)
  40--59                                           32 829 (31·4%)    160 319 (31·5%)
  60--79                                           23 810 (22·8%)    115 165 (22·6%)
  ≥ 80                                             4223 (4%)         19 874 (3·9%)
  Index year (% of *n*)                                              
  1999                                             3959 (3·8%)       20 202 (4%)
  2000                                             4951 (4·7%)       24 275 (4·8%)
  2001                                             5806 (5·6%)       28 564 (5·6%)
  2002                                             6740 (6·5%)       33 226 (6·5%)
  2003                                             7460 (7·1%)       36 329 (7·1%)
  2004                                             7723 (7·4%)       37 543 (7·4%)
  2005                                             7995 (7·7%)       39 012 (7·7%)
  2006                                             7985 (7·6%)       38 992 (7·7%)
  2007                                             8274 (7·9%)       40 320 (7·9%)
  2008                                             8485 (8·1%)       41 008 (8·1%)
  2009                                             8058 (7·7%)       39 116 (7·7%)
  2010                                             7336 (7%)         35 630 (7%)
  2011                                             7182 (6·9%)       34 554 (6·8%)
  2012                                             6703 (6·4%)       32 367 (6·4%)
  2013                                             5784 (5·5%)       27 319 (5·4%)
  Practice‐level deprivation quintile (% of *n*)                     
  1 (least deprived)                               18 908 (18·1%)    92 132 (18·1%)
  2                                                20 231 (19·4%)    98 468 (19·4%)
  3                                                21 436 (20·5%)    104 330 (20·5%)
  4                                                21 539 (20·6%)    104 793 (20·6%)
  5 (most deprived)                                22 327 (21·4%)    108 734 (21·4%)
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The results of the mortality analysis are shown in Table [3](#bjd15021-tbl-0003){ref-type="table-wrap"}. We observed a significant interaction between psoriasis and age at index date. Patients in the reference age category (40--59 years) with psoriasis had a 20% higher mortality rate than their matched controls \[hazard ratio (HR) 1·2, 95% CI 1·12--1·28\]. In the youngest group (0--19 years), increased mortality associated with psoriasis appeared even higher, although small numbers of patients in this group resulted in wider confidence intervals (HR 1·53, 95% CI 1·02--2·3). Mortality among patients diagnosed with psoriasis at an older age did not appear to be increased (age 60--79 years: HR 1·08, 95% CI 0·99--1·16; age 80+ years: HR 0·99, 95% CI 0·91--1·08). There was an overall reduction in mortality over time for all patients (HR 0·92 per year, 95% CI 0·91--0·92), with no evidence that this differed between those with and without psoriasis (i.e. no significant interaction). Figure [4](#bjd15021-fig-0004){ref-type="fig"} shows reductions in mortality rates for patients with and without psoriasis over the 15‐year study period. Results were similar when we limited the cohort to include only those practices that contributed data for the entire period of the study (Table S2, see Supporting Information). In this sensitivity analysis, the HR for psoriasis in the reference group was 1·25 (95% CI 1·13--1·37).

###### 

Results of the Cox regression analysis examining the risk of mortality in patients with psoriasis. 'Age' represents age at index date; age 40--59 is the reference category)

  Variable                                                        HR (95% CI)           Coefficient (se)   z          *P*--value
  --------------------------------------------------------------- --------------------- ------------------ ---------- ---------------
  Index year                                                      0·92 (0·91--0·92)     --0·086 (0·002)    --40·218   **\< 0·0001**
  Women                                                           0·7 (0·66--0·74)      --0·36 (0·029)     --12·439   **\< 0·0001**
  Age 0--19                                                       0·07 (0·05--0·09)     --2·667 (0·122)    --21·926   **\< 0·0001**
  Age 20--39                                                      0·22 (0·2--0·24)      --1·531 (0·05)     --30·598   **\< 0·0001**
  Age 60--79                                                      5·6 (5·34--5·87)      1·722 (0·024)      70·981     **\< 0·0001**
  Age ≥ 80                                                        25·2 (23·71--26·83)   3·228 (0·032)      102·398    **\< 0·0001**
  IMD 2[a](#bjd15021-note-0003){ref-type="fn"}                    1·07 (1·01--1·14)     0·072 (0·031)      2·302      **0·0213**
  IMD 3[a](#bjd15021-note-0003){ref-type="fn"}                    1·12 (1·06--1·18)     0·113 (0·028)      3·997      **0·0001**
  IMD 4[a](#bjd15021-note-0003){ref-type="fn"}                    1·22 (1·14--1·29)     0·195 (0·031)      6·218      **\< 0·0001**
  IMD 5[a](#bjd15021-note-0003){ref-type="fn"}                    1·38 (1·3--1·47)      0·324 (0·032)      10·243     **\< 0·0001**
  Psoriasis                                                       1·21 (1·13--1·3)      0·19 (0·036)       5·374      **\< 0·0001**
  Female : Age 0--19[b](#bjd15021-note-0003){ref-type="fn"}       0·75 (0·53--1·06)     --0·288 (0·178)    --1·623    0·1045
  Female : Age 20--39[b](#bjd15021-note-0003){ref-type="fn"}      0·85 (0·74--0·98)     --0·164 (0·073)    --2·234    **0·0255**
  Female : Age 60--79[b](#bjd15021-note-0003){ref-type="fn"}      1·01 (0·95--1·08)     0·013 (0·033)      0·382      0·7022
  Female : Age ≥ 80[b](#bjd15021-note-0003){ref-type="fn"}        1·11 (1·03--1·21)     0·108 (0·04)       2·693      **0·0071**
  Age 0--19 : psoriasis[b](#bjd15021-note-0003){ref-type="fn"}    1·27 (0·85--1·89)     0·236 (0·204)      1·156      0·2479
  Age 20--39 : psoriasis[b](#bjd15021-note-0003){ref-type="fn"}   0·88 (0·73--1·06)     --0·129 (0·094)    --1·373    0·1698
  Age 60--79 : psoriasis[b](#bjd15021-note-0003){ref-type="fn"}   0·89 (0·83--0·96)     --0·115 (0·04)     --2·896    **0·0038**
  Age ≥ 80 : psoriasis[b](#bjd15021-note-0003){ref-type="fn"}     0·82 (0·75--0·9)      --0·199 (0·044)    --4·54     **\< 0·0001**
  Index year : psoriasis[b](#bjd15021-note-0003){ref-type="fn"}   1·01 (1--1·01)        0·005 (0·004)      1·256      0·209

CI, confidence interval; HR, hazard ratio; IMD, Index of Multiple Deprivation, quintile. *P*‐values significant at the 0·05 level are marked in bold. ^a^Quintile 1 (least deprived) is the reference category. ^b^Interactions between variables are indicated by a colon.
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![Temporal trends in mortality in patients with psoriasis (case) and without psoriasis (control).](BJD-176-650-g004){#bjd15021-fig-0004}

Discussion {#bjd15021-sec-0014}
==========

We found that over a 15‐year period (between 1999 and 2013), psoriasis prevalence steadily increased and our latest estimates suggest that psoriasis now affects over 2·8% of the general population in the U.K. At the same time, mortality in patients with psoriasis and to a lesser extent incident cases of psoriasis has decreased. All‐cause mortality rates for patients with psoriasis remain elevated compared with patients without psoriasis and we found no significant change in this relative premature mortality gap over time. These findings show that there is an increasing population living longer with psoriasis, which has important implications for healthcare service delivery. Within the U.K., we observed positive associations between incidence and prevalence of psoriasis and latitude. We also found a clear bimodal pattern in incidence of psoriasis when examined against patient age, supporting the notion of 'type I' (early‐onset) and 'type II' (late‐onset) variants of the condition.

An increasing trend in psoriasis prevalence has been observed in several settings before, for example in the U.S.A., Norway and Spain.[19](#bjd15021-bib-0019){ref-type="ref"}, [20](#bjd15021-bib-0020){ref-type="ref"}, [21](#bjd15021-bib-0021){ref-type="ref"}, [22](#bjd15021-bib-0022){ref-type="ref"}, [23](#bjd15021-bib-0023){ref-type="ref"} This observed increase in prevalence of psoriasis has been speculated to be related to a better awareness of the disease among physicians and in the general population (possibly due to the advent of biologic therapies) rather than a real increase in the prevalence of the disease.[23](#bjd15021-bib-0023){ref-type="ref"} In this study, we were able to consider this steady increase in psoriasis in the context of a decreasing risk of mortality. As fewer patients die for every incident case over time, we found that the prevalence pool of patients with psoriasis is steadily increasing.

Studies of the incidence of psoriasis longitudinally are scarce. Results from two earlier cross‐sectional studies in the U.S.A. suggested an increasing trend of incident cases of psoriasis over a 30‐year period both in children[24](#bjd15021-bib-0024){ref-type="ref"} and in adults.[25](#bjd15021-bib-0025){ref-type="ref"} The reasons behind the suggested increasing trend were unknown, but included a variety of potential explanations, among which were a true change in incidence of psoriasis, a change in the diagnosis patterns over time[25](#bjd15021-bib-0025){ref-type="ref"} or an increase in risk factors for psoriasis such as obesity.[24](#bjd15021-bib-0024){ref-type="ref"} Our findings relating to age of onset of psoriasis show a clear separation between incidence of early‐ and late‐onset psoriasis ('type I' and 'type II'), corresponding to whether the diagnosis is made at ≤ 40 or \> 40 years of age.[26](#bjd15021-bib-0026){ref-type="ref"} In early‐onset psoriasis, females have a higher incidence of psoriasis and the peak of early‐onset psoriasis occurs in their late teens and early twenties. This pattern reflects previously reported more rapid increase in psoriasis prevalence in women.[27](#bjd15021-bib-0027){ref-type="ref"} The corresponding peak of early‐onset psoriasis in men appeared later -- in their thirties. This difference was not observed in late‐onset psoriasis in which the pattern of incidence by age did not appear to differ between males and females.

However, latitude appeared to have a significant effect on psoriasis, with around 6·5 new psoriasis cases per 100 000 for every degree increase in latitude in the U.K. Our earlier systematic review of the global epidemiology of psoriasis noted that the prevalence of psoriasis varied between geographic regions, with psoriasis appearing more commonly in countries more distant from the equator.[4](#bjd15021-bib-0004){ref-type="ref"} Likely mechanisms for these findings include the degree of solar irradiance and the metabolism of vitamin D. Vitamin D analogues are well established as an effective treatment for mild‐to‐moderate psoriasis when applied topically and phototherapy has been used widely to treat psoriasis that cannot be controlled with topical treatment alone. Further studies of the effects of solar irradiance and latitude on the incidence and prevalence of psoriasis in other settings are needed to confirm this relationship with disease epidemiology.

To our knowledge, we present the first study to examine simultaneously trends in incidence, prevalence and mortality of patients with psoriasis over a prolonged period in a large representative sample of the general population. In considering these epidemiological measures concurrently, we found that the increasing survival of patients with psoriasis is contributing to the increased prevalence of the condition in the U.K. Although the size and validity of the database used allowed us to investigate these trends effectively, some important limitations remain that should be considered alongside our findings. Firstly, psoriasis cases were identified from general practice electronic health records using relevant diagnostic code lists and so may not necessarily have been verified by dermatologists. However, in the U.K., primary care is fully computerized and appropriate coding in clinical computer systems is considered standard practice.[28](#bjd15021-bib-0028){ref-type="ref"} Previous studies have shown that primary care electronic health records in the U.K. are a valid data resource for studying psoriasis.[29](#bjd15021-bib-0029){ref-type="ref"}, [30](#bjd15021-bib-0030){ref-type="ref"} A limitation, nonetheless, is that our study includes only those patients who present in general practice and thereby receive a physician diagnosis of psoriasis, but this would also be true in other patient populations.

For the first time, we provide a comprehensive longitudinal picture of the prevalence and incidence of psoriasis, and mortality rates over a 15‐year period. We present a rise in the prevalence of diagnosed psoriasis in the U.K., between 1999 and 2013, which does not appear to be attributable to a corresponding increase in incidence. We found that there is an increasing population living longer with psoriasis in the U.K., which has resulted in an increase in the prevalence and this has important implications for healthcare service delivery and for resource allocation. We observed peaks in age bands characteristic of early‐ and late‐onset psoriasis, and changes in incidence and prevalence rates with increasing latitude. All‐cause mortality rates for patients with psoriasis have decreased over the last 15 years, but remain elevated compared with patients without psoriasis. Importantly, we found no significant change in this premature mortality gap over time.

Supporting information
======================

###### 

**Table S1.** Unadjusted incidence and prevalence numerators, denominators and rates. Values are shown for males and females split by year.

**Table S2.** Results of the Cox regression analysis examining the risk of mortality in patients with psoriasis in the cohort reduced to those practices contributing data continuously between 1999 and 2013.

**Fig S1.** Incidence and prevalence (95% confidence intervals) of psoriasis in continuously contributing Clinical Practice Research Datalink practices from 1999 to 2013 for both men and women.

###### 

Click here for additional data file.

This study is based on data from the Clinical Practice Research Datalink (CPRD) obtained under license from the U.K. Medicines and Healthcare Products Regulatory Agency. The study has been approved by the Independent Scientific Advisory Committee for CPRD research (reference number: 14_134RA). C.E.M.G. is a National Institute for Health Research Senior Investigator.
